n. a *tissue-type plasminogen activator made by recombinant DNA technology (genetic engineering). Alteplase is used to dissolve blood clots (see fibrinolytic) in the treatment of ischaemic stroke, myocardial infarction, and pulmonary embolism. Possible side-effects include local bleeding, cerebral haemorrhage, nausea, and vomiting.
A group of drugs, also known as thrombolytics, with the ability to break down the protein FIBRIN, the prime constituent of blood clots (see THROMBUS; THROMBOSIS). They are used to disperse blood clots that have formed in the vessels of the circulatory system. The group includes STREPTOKINASE, alteplase and reteplase. The drugs work by activating PLASMINOGEN to form PLASMIN which degrades ?brin and breaks up the blood clot (see COAGULATION).... fibrinolytic drugs
A substance produced by body tissues that prevents abnormal blood clotting. Also called , it is produced by the inner lining of blood vessels. can be prepared artificially for use as a thrombolytic drug, which is called alteplase. This is used in the treatment of myocardial infarction, severe angina pectoris, and arterial embolism, including pulmonary embolism. Possible side effects include bleeding or the formation of a haematoma at the injection site and an allergic reaction. (See also fibrinolysis.)... tissue-plasminogen activator
adj. describing a group of drugs that are capable of breaking down the protein fibrin (see fibrinolysis), which is the main constituent of blood clots, and are therefore used to disperse blood clots (thrombi) that have formed within the circulation, most notably after myocardial infarction. They include *streptokinase, *urokinase, *alteplase, reteplase, and tenecteplase. Possible side-effects include bleeding at needle puncture sites, headache, backache, blood spots in the skin, and allergic reactions.... fibrinolytic
(tPA, TPA) a natural protein, found in the body and able to be manufactured by genetic engineering, that can break up a thrombus (see thrombolysis). It requires the presence of *fibrin as a cofactor and is able to activate *plasminogen on the fibrin surface, which distinguishes it from the other plasminogen activators, *streptokinase and *urokinase. tPAs include reteplase and tenecteplase, given to treat acute myocardial infarction, and *alteplase.... tissue-type plasminogen activator
Health Encyclopedia